All clinical research involving human subjects in France is strictly regulated by the Jardé Law, which ensures that every study undergoes a thorough ethical review by a Comité de Protection des Personnes (CPP). In late 2025, the process of CPP allocation remains randomized through a national web portal to ensure impartiality and a balanced workload across the different regional committees. For research organizations, this means that a trial must be designed to meet the highest ethical standards of patient safety and data privacy regardless of which committee is assigned to the review. The France Contract Research Organization Sector notes that this robust ethical framework is a cornerstone of public trust in the French medical system, ensuring that participants are fully informed and protected throughout the duration of their involvement in a study.

Frequently Asked Questions

Q. What is the role of a CPP? A. The CPP is an independent ethics committee that reviews the medical and social relevance of a trial and ensures that the protection of participants is guaranteed.

Q. Can a sponsor choose which CPP reviews their trial? A. No, in France, the committee is assigned randomly by a national system to ensure there is no conflict of interest or bias in the approval process.